HBV-related hepatocarcinogenesis: the role of signalling pathways and innovative ex vivo research models

Joseph Torresi; Manh Tran Bang; Dale Christiansen; Linda Earnest-Silveira; Renate Hilda Marianne Schwab; Elizabeth Vincan

Journal article

HBV-related hepatocarcinogenesis: the role of signalling pathways and innovative ex vivo research models

Joseph Torresi, Manh Tran Bang, Dale Christiansen, Linda Earnest-Silveira, Renate Hilda Marianne Schwab, Elizabeth Vincan

BMC CANCER | BMC | Published : 2019

DOI: 10.1186/s12885-019-5916-6

Download PDF

Abstract

BACKGROUND: Hepatitis B virus (HBV) is the leading cause of liver cancer, but the mechanisms by which HBV causes liver cancer are poorly understood and chemotherapeutic strategies to cure liver cancer are not available. A better understanding of how HBV requisitions cellular components in the liver will identify novel therapeutic targets for HBV associated hepatocellular carcinoma (HCC). MAIN BODY: The development of HCC involves deregulation in several cellular signalling pathways including Wnt/FZD/β-catenin, PI3K/Akt/mTOR, IRS1/IGF, and Ras/Raf/MAPK. HBV is known to dysregulate several hepatocyte pathways and cell cycle regulation resulting in HCC development. A number of these HBV induced..

View full abstract

University of Melbourne Researchers

Joseph Torresi Author Microbiology and Immunology

Linda Earnest Author Microbiology and Immunology

Bang Tran Author Infectious Diseases

Elizabeth Vincan Author Infectious Diseases

Related Projects (2)

FZD7 AS A THERAPEUTIC TARGET FOR GASTRIC CANCER

Fzd receptors are often upregulated in gastric cancer, and recent studies have shown that targeting these receptors has be effective at redu..

Molecules involved in gut development and bowel cancer

Wnt proteins are a family of signaling molecules that are critical for the function of normal and cancerous epithelial cells in the gut. How..

Grants

Awarded by National Health and Medical Research Council of Australia (NHMRC)

Awarded by Melbourne Health project grants

Awarded by NHMRC Practitioner Fellowship

Funding Acknowledgements

Funding is gratefully acknowledged from the following; National Health and Medical Research Council of Australia (NHMRC) project grants (566679 and APP1099302) and Melbourne Health project grants (605030 and PG-002) awarded to EV. JT is supported by an NHMRC Practitioner Fellowship, number 106043. Funding bodies did not fund this review specifically but supported the research in our laboratories that led to some of our conclusions.